In addition to phenotypic differences, Ward et al. demonstrated increased Rho-GTP levels in prostate cancer through signaling mediated by CD97 and its association with lysophosphatidic acid receptor 1 (LPAR1) and subsequent ERK activation16. Here, LPAR1 is linked to prostate carcinoma.